{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:48:50Z","timestamp":1791600530307,"version":"4.3.4"},"reference-count":27,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Immune checkpoint inhibitor-related hepatitis (ICI-H) can resemble classical autoimmune hepatitis (AIH), but comparative multidomain data remain limited. We compared their clinical, biochemical, and serological profiles and descriptively summarized histopathological findings. Methods: This single-centre retrospective cohort screened 100 records from January 2018 to October 2023; 79 patients met predefined criteria (40 ICI-H; 39 AIH). ICI-H required an updated RUCAM score of \u22656, whereas AIH required a simplified AIH score of \u22656 and compatible histology. Continuous and categorical variables were assessed using Mann\u2013Whitney U and Fisher\u2019s exact tests with Benjamini\u2013Hochberg correction where applicable; histopathological findings were summarized descriptively because biopsy ascertainment was markedly unequal between groups. Results: Compared with AIH, ICI-H occurred more often in men (65.0% vs. 20.5%) and showed higher AST, ALT, ALP, GGT, INR, CRP, and neutrophil-to-lymphocyte ratio (all q &lt; 0.001), but lower ANA positivity (12.5% vs. 74.4%; q &lt; 0.001). Histopathological observations were limited to the biopsy-assessed subgroup (10 ICI-H; 39 AIH) and are reported descriptively because biopsy ascertainment was markedly unequal and non-random. Conclusions: ICI-H and classical AIH showed different observed clinical, biochemical, and serological profiles; however, these differences should not be interpreted as independent diagnostic discriminators because disease-specific criteria contributed to group assignment. Diagnosis after ICI exposure should integrate exposure timing, exclusion of competing causes, structured causality assessment, serology, and selective histology. Outcome comparisons require standardized longitudinal follow-up.<\/jats:p>","DOI":"10.3390\/jcm15197572","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:14:37Z","timestamp":1790694877000},"page":"7572","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune Checkpoint Inhibitor-Related Hepatitis Versus Classical Autoimmune Hepatitis: A Retrospective Multidomain Phenotype Comparison"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8222-2384","authenticated-orcid":false,"given":"Mehmet Kursad","family":"Keskin","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Bursa Uluda\u011f University, Bursa 16059, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2444-6587","authenticated-orcid":false,"given":"Alper","family":"Coskun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Bursa Uluda\u011f University, Bursa 16059, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]},{"given":"Nesrin","family":"Ugras","sequence":"additional","affiliation":[{"name":"Department of Medical Pathology, Faculty of Medicine, Bursa Uluda\u011f University, Bursa 16059, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"data-curation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Erdem","family":"Cubukcu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Bursa Uluda\u011f University, Bursa 16059, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim Giray","family":"Nak","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Bursa Uluda\u011f University, Bursa 16059, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"supervision","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"Michot","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/liv.14489","article-title":"Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors","volume":"40","author":"Viladomiu","year":"2020","journal-title":"Liver Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100719","DOI":"10.1016\/j.jhepr.2023.100719","article-title":"Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort","volume":"5","author":"Hountondji","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100851","DOI":"10.1016\/j.jhepr.2023.100851","article-title":"Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study","volume":"5","author":"Atallah","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41575-024-01019-7","article-title":"Immune-mediated liver injury from checkpoint inhibitors: Mechanisms, clinical characteristics and management","volume":"22","author":"Triantafyllou","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.dld.2023.06.014","article-title":"Long-term outcome of autoimmune hepatitis: Consecutive patient cohort and data on the second twenty years","volume":"55","author":"Harrison","year":"2023","journal-title":"Dig. Liver Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00432-021-03870-6","article-title":"Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients","volume":"148","author":"Purde","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e005635","DOI":"10.1136\/jitc-2022-005635","article-title":"Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events","volume":"10","author":"Coukos","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.15403\/jgld-5045","article-title":"Clinical and pathological features of immune checkpoint inhibitor-induced liver injury in comparison with drug-induced liver injury and autoimmune hepatitis","volume":"32","author":"Sunago","year":"2023","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: A histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Parlati, L., Marcin, K., Terris, B., Vallet-Pichard, A., Corouge, M., Hollande, C., Sogni, P., Mallet, V., and Pol, S. (2023). Histological characteristics and management of hepatitis on immune checkpoint inhibitors: A retrospective descriptive study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12113751"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e00988","DOI":"10.1097\/HC9.0000000000000988","article-title":"Liver biopsy findings and clinical correlates in immune-mediated liver injury from checkpoint inhibitors","volume":"10","author":"Meunier","year":"2026","journal-title":"Hepatol. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e014178","DOI":"10.1136\/jitc-2025-014178","article-title":"Circulating exhausted CD8+ effector memory cells differentiate immune checkpoint inhibitor-induced liver injury from other acute immune-mediated liver injuries","volume":"14","author":"Astbury","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"113313","DOI":"10.1016\/j.ejca.2023.113313","article-title":"Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology","volume":"193","author":"Alouani","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/hepr.14078","article-title":"Diagnostic guide for immune checkpoint inhibitor-induced liver injury","volume":"54","author":"Ito","year":"2024","journal-title":"Hepatol. Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Danan, G., and Teschke, R. (2016). RUCAM in drug and herb induced liver injury: The update. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17010014"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/apt.18276","article-title":"Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury, as assessed for causality using the updated RUCAM","volume":"60","author":"Hountondji","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_21","unstructured":"National Cancer Institute (2026, August 11). Common Terminology Criteria for Adverse Events (CTCAE), Available online: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"ref_22","unstructured":"European Association for the Study of the Liver (2025). EASL Clinical Practice Guidelines on the management of autoimmune hepatitis. J. Hepatol., 83, 453\u2013501."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1136\/gutjnl-2024-333171","article-title":"British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis","volume":"74","author":"Gleeson","year":"2025","journal-title":"Gut"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group report: Review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/liv.15217","article-title":"Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology","volume":"42","author":"Lohse","year":"2022","journal-title":"Liver Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jhep.2021.12.041","article-title":"Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group","volume":"76","author":"Pape","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.hpb.2021.06.414","article-title":"Superiority of CRP-albumin-lymphocyte index (CALLY index) as a non-invasive prognostic biomarker after hepatectomy for hepatocellular carcinoma","volume":"24","author":"Iida","year":"2022","journal-title":"HPB"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7572\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:53:49Z","timestamp":1791597229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":27,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["jcm15197572"],"URL":"https:\/\/doi.org\/10.3390\/jcm15197572","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]}}}